Lack of involvement of dopamine and serotonin during the orphanin FQ/Nociceptin (OFQ/N)-induced prolactin secretory response.
The purpose of these studies was to examine possible mechanisms of Orphanin FQ/Nociceptin (OFQ/N)-induced prolactin release. We investigated the involvement of the dopaminergic neurons by quantifying DOPAC:DA levels in the median eminence and neurointermediate lobe following central administration of OFQ/N to female Sprague-Dawley rats. To specifically determine the involvement of the tuberoinfundibular dopaminergic neurons, immunocytochemical studies were conducted to visualize c-fos protein expression in the arcuate nucleus following central administration of OFQ/N. In addition, the role of serotonergic activation was examined in dose response studies using the selective serotonin antagonist ritansarin and the nonselective antagonist metergoline. Finally, the pharmacological specificity of the prolactin response was examined by pretreating animals with [Nphe1] NC (1-13)NH2, a drug reported to antagonize OFQ/N effects. The results of these studies indicate that the increase in prolactin release following central administration of OFQ/N does not inhibit tuberoinfundibular, tuberohypophyseal or periventricular hypophysial dopaminergic neuronal activity at 10 min after drug administration, a time when prolactin levels were significantly elevated. Furthermore, serotonergic activation is not involved since pharmacological blockade of serotonergic receptors did not alter the prolactin secretory response to OFQ/N. NC (1-13)NH2 did not antagonize the stimulatory effects of OFQ/N on prolactin secretion. The neural effects of OFQ/N on dopaminergic neuronal activity may occur following a different time course than that of the prolactin increase.
Kraska
Amy
A
Department of Zoology, Center for Neuroscience, Miami University, Oxford, OH 45056, USA.
Bryant
Winnifred
W
Murphree
Emily
E
Callahan
Phyllis
P
Janik
James
J
D000818:Animals; D001111:Arcuate Nucleus of Hypothalamus / Q000737:chemistry / Q000187:drug effects; D004298:Dopamine / Q000502:physiology*; D005260:Female; D007150:Immunohistochemistry; D008473:Median Eminence / Q000187:drug effects / Q000502:physiology; D008711:Metergoline / Q000494:pharmacology; D009020:Morphine / Q000494:pharmacology; D018847:Opioid Peptides / Q000494:pharmacology*; D011388:Prolactin / Q000378:metabolism*; D016760:Proto-Oncogene Proteins c-fos / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D016713:Ritanserin / Q000494:pharmacology; D012701:Serotonin / Q000502:physiology*; D000097629:Nociceptin
D004298:Dopamine; D008711:Metergoline; D009020:Morphine; D018847:Opioid Peptides; D011388:Prolactin; D016760:Proto-Oncogene Proteins c-fos; D016713:Ritanserin; D012701:Serotonin; D000097629:Nociceptin